Glenmark subsidiary signs agreement with BeiGene to market, distribute Tislelizumab and Zanubrutinib

Glenmark Pharmaceuticals on Tuesday announced that its subsidiary Glenmark Speciality S.A. entered into an exclusive agreement with BeiGene, a global oncology company, to market and distribute Tislelizumab and Zanubrutinib. Under the agreement, Glenmark will register and commercialise the medicines in India. Shares of Glenmark were trading lower by 0.76% on Tuesday.

Tislelizumab is a novel anti-PD-1 monoclonal antibody that is used in the treatment of advanced or metastatic esophageal squamous cell carcinoma and broad development for the treatment of various types of cancers. Tislelizumab has received approval from the National Medical Products Administration (NMPA), the European Medicines Agency (EMA), and the United States Food and Drug Administration (USFDA).

Zanubrutinib is a small molecule inhibitor of Bruton’s tyrosine kinase (BTK) that has been approved for the treatment of certain hematological malignancies.

The company pointed out that India has the third highest number of cancer cases worldwide according to recent statistics. The number of cancer cases in India is projected to reach 2.08 million cases by 2040. India is also third highest in the number of blood cancer cases which results in 70,000 deaths each year.

Glenmark Pharmaceuticals recently announced that the company has received approval from the USFDA for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%|0.5%. According to the FDA, Glenmark’s abbreviated new drug application (ANDA) for the solution is bioequivalent and therapeutically equivalent to Combigan’s Ophthalmic Solution, 0.2%|0.5%, of AbbVie Inc. Glenmark Pharmaceuticals, USA will distribute the solution in the United States. The company is set to announce its fourth quarter and fiscal year 2024 results on May 24, 2024.

Shares of the company have risen by nearly 21% since the beginning of the year. The stock has gained nearly 71% in the last one year.